Mandate

Vinge is advising Medivir in connection with its rights issue

December 14, 2020 Capital Markets and Public M&A

Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir with issue proceeds amounting to a maximum of SEK 170 million, as well as with an over-allotment option by way of a directed share issue of a maximum of approximately SEK 25 million.

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

Medivir is listed on Nasdaq Stockholm, Small Cap.

Vinge’s team mainly consisted of Dain Hård Nevonen, Amanda Knutsson, Julia Hirschberg and Olof Löfvenberg.

Related

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024

Vinge has advised Embracer Group in connection with a EUR 900 million bridge facility agreement entered into with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank

Vinge has advised Embracer Group AB (publ) (“Embracer”) and its subsidiary group Asmodee in connection with the entry into of a EUR 900,000,000 financing agreement with JP Morgan, BNP Paribas, SEB, Société Générale and Swedbank and concurrent prepayment of existing Embracer indebtedness.
April 22, 2024

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024